We transform promising life science ideas into medical breakthroughs that change patients’ lives.
Making life science life changing: We transform promising life science ideas into medical breakthroughs that change patients’ lives.
We specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.
MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. They are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.
London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.
MedCity's ambition is for their region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.
At Nanovery, their cutting-edge DNA nanorobots are revolutionising the biotechnology landscape. As pioneers in nucleic acid nanorobotics (NANs), our platform is the first to provide comprehensive solutions for RNA therapeutic analysis and biomarker quantification. This innovation elevates research precision and simplifies testing protocols.
Their mission is to make the testing processes as simple as possible to drive advancements in biotech research. Nanovery's NANs technology is not just part of biotechnology's future; it is actively shaping it, ensuring their partners stay at the forefront of innovation.
Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases.
The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.
The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
